How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

129,191 results for

Demulen 1/35

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Nivolumab (melanoma): Addendum to Commission A16-35

Nivolumab (melanoma): Addendum to Commission A16-35 Nivolumab (Melanom): Addendum zum Auftrag A16-35; Auftrag A16-68 [Nivolumab (melanoma): Addendum to Commission A16-35] Nivolumab (Melanom): Addendum zum Auftrag A16-35; Auftrag A16-68 [Nivolumab (melanoma): Addendum to Commission A16-35] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (Melanom): Addendum zum Auftrag A16-35; Auftrag A16-68. [Nivolumab (melanoma): Addendum to Commission A16-35] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 465. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Melanoma Language Published German Country

2016 Health Technology Assessment (HTA) Database.

22. Changes in the spatial distribution of the under-five mortality rate: Small-area analysis of 122 DHS surveys in 262 subregions of 35 countries in Africa. (PubMed)

Changes in the spatial distribution of the under-five mortality rate: Small-area analysis of 122 DHS surveys in 262 subregions of 35 countries in Africa. The under-five mortality rate (U5MR) is a critical and widely available population health indicator. Both the MDGs and SDGs define targets for improvement in the U5MR, and the SDGs require spatial disaggregation of indicators. We estimate trends in the U5MR for Admin-1 subnational areas using 122 DHS surveys in 35 countries in Africa (...) and assess progress toward the MDG target reductions for each subnational region and each country as a whole. In each country, direct weighted estimates of the U5MR from each survey are calculated and combined into a single estimate for each Admin-1 region across five-year periods. Our method fully accounts for the sample design of each survey. The region-time-specific estimates are smoothed using a Bayesian, space-time model that produces more precise estimates (when compared to the direct estimates

Full Text available with Trip Pro

2019 PLoS ONE

23. Corrigendum to CSF-1 receptor signalling is governed by pre-requisite EHD1 mediated receptor display on the macrophage cell surface [Cell Signalling 2016 Sep.; 28(9): 1325–35] (PubMed)

Corrigendum to CSF-1 receptor signalling is governed by pre-requisite EHD1 mediated receptor display on the macrophage cell surface [Cell Signalling 2016 Sep.; 28(9): 1325–35] 27510742 2018 07 27 1873-3913 28 12 2016 12 Cellular signalling Cell. Signal. Corrigendum to CSF-1 receptor signalling is governed by pre-requisite EHD1 mediated receptor display on the macrophage cell surface [Cell Signalling 2016 Sep.; 28(9): 1325-35]. 1933 S0898-6568(16)30198-X 10.1016/j.cellsig.2016.07.018 Cypher (...) Biology, & Anatomy, University of Nebraska Medical Center, Omaha, NE, United States. Electronic address: hband@unmc.edu. eng R01 CA087986 CA NCI NIH HHS United States R01 CA144027 CA NCI NIH HHS United States R01 CA099900 CA NCI NIH HHS United States R01 CA099163 CA NCI NIH HHS United States T32 CA009476 CA NCI NIH HHS United States Journal Article Published Erratum 2016 08 07 England Cell Signal 8904683 0898-6568 Cell Signal. 2016 Sep;28(9):1325-35 27224507 2016 8 12 6 0 2016 8 12 6 1 2016 8 12 6 0

Full Text available with Trip Pro

2016 Cellular signalling

24. Ortho-Novum 1/35

Ortho-Novum 1/35 Ortho-Novum 1/35 Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Ortho-Novum 1/35 Ortho-Novum 1/35 Aka: Ortho-Novum 1 (...) /35 , Ortho Novum 1/35 , Norinyl , Norinyl 1/35 , Necon , Dasetta , Alyacen , Nortrel 1/35 , Norimin , Pirmella 1/35 II. Preparations (Norethindrone / Ethinyl Estradiol) Ortho Novum 1/35, Norinyl 1/35, Nortrel 1/35, Necon, Dasetta or Alyacen Norimin (UK) III. Components 1.0 mg (see preparations above) 35 ug IV. Effect Relative : 1.0 (moderate) : 38 (high) : 0.34 (moderate) V. Pill associated problems Indications to switch to (lower androgen) Increased Appetite (lower ) provoked (lower

2018 FP Notebook

25. Kinetic study of laboratory mutants of NDM-1 metallo-β-lactamase: the importance of an isoleucine at position 35. (PubMed)

Kinetic study of laboratory mutants of NDM-1 metallo-β-lactamase: the importance of an isoleucine at position 35. Two laboratory mutants of NDM-1 were generated by replacing the isoleucine at position 35 with threonine and serine residues: the NDM-1(I35T)and NDM-1(I35S)enzymes. These mutants were well characterized, and their kinetic parameters were compared with those of the NDM-1 wild type. Thekcat,Km, andkcat/Kmvalues calculated for the two mutants were slightly different from those (...) of the wild-type enzyme. Interestingly, thekcat/Kmof NDM-1(I35S)for loracarbef was about 14-fold higher than that of NDM-1. Far-UV circular dichroism (CD) spectra of NDM-1 and NDM-1(I35T)and NDM-1(I35S)enzymes suggest local structural rearrangements in the secondary structure with a marked reduction of α-helix content in the mutants. Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Full Text available with Trip Pro

2016 Antimicrobial Agents and Chemotherapy

26. Hyaluronan 35 kDa treatment protects mice from Citrobacter rodentium infection and induces epithelial tight junction protein ZO-1 in vivo (PubMed)

Hyaluronan 35 kDa treatment protects mice from Citrobacter rodentium infection and induces epithelial tight junction protein ZO-1 in vivo Maintaining a healthy intestinal barrier, the primary physical barrier between intestinal microbiota and the underlying lamina propria, is critical for optimal health. Epithelial integrity is essential for the prevention of the entrance of luminal contents, such as bacteria and their products, through the large intestinal barrier. In this study, we (...) protein zonula occludens (ZO)-1 in both healthy and Citrobacter infected mice, as demonstrated by immunoflurorescence and Western blot analyses. Furthermore, we determined that HA35 treatment enhances ZO-1 expression and reduces intestinal permeability at the early stages of dextran sulfate sodium (DSS)-induced colitis in mice. Together, our data demonstrate that the expression and functionality of tight junctions, are increased by HA35 treatment, suggesting a novel mechanism for the protection from

Full Text available with Trip Pro

2016 Matrix biology : journal of the International Society for Matrix Biology

27. DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury (PubMed)

DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury Stroke induces a catastrophic immune response that involves the global activation of peripheral leukocytes, especially T cells. The human leukocyte antigen-DRα1 domain linked to MOG-35-55 peptide (DRα1-MOG-35-55) is a partial major histocompatibility complex (MHC) class II construct which can inhibit neuroantigen-specific T cells and block binding of the cytokine/chemokine macrophage migration inhibitory factor (MIF) to its CD74 receptor (...) on monocytes and macrophages. Here, we evaluated the therapeutic effect of DRα1-MOG-35-55 in a mouse model of permanent distal middle cerebral artery occlusion (dMCAO). DRα1-MOG-35-55 was administered to WT C57BL/6 mice by subcutaneous injection starting 4 h after the onset of ischemia followed by three daily injections. We demonstrated that DRα1-MOG-35-55 post treatment significantly reduced brain infarct volume, improved functional outcomes, and inhibited the accumulation of CD4+ and CD8+ T cells

Full Text available with Trip Pro

2016 Translational stroke research

28. Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35

Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35 1 Translation of addendum A18-05 Sofosbuvir/Velpatasvir/Voxilaprevir (Chronische Hepatitis C) – Addendum zum Auftrag A17-35 (Version 1.0; Status: 25 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 25 January 2018 1.0 Commission: A18-05 Version (...) : Status: IQWiG Reports – Commission No. A18-05 Sofosbuvir/velpatasvir/ voxilaprevir (chronic hepatitis C) – Addendum to Commission A17-35 1 Addendum A18-05 Version 1.0 Sofosbuvir/velpatasvir/voxilaprevir – Addendum to Commission A17-35 25 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – Addendum to Commission A17-35

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

29. Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35-42 years with a body weight ≥50 kg: a randomized controlled trial. (PubMed)

centre in Vietnam from June 2015 to August 2016. A total of 400 patients were included, 200 in each treatment group. The primary outcome measure was the number of oocytes retrieved. Patients were followed for 1 year after randomization.Participants aged 35-42 years with a body weight ≥50 kg who were undergoing an IVF cycle were randomized to undergo COS with a single dose of corifollitropin alfa 150 μg on Day 2 or 3 of the menstrual cycle, or follitropin beta 300 IU/day for 7 days starting on Day 2 (...) Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35-42 years with a body weight ≥50 kg: a randomized controlled trial. Is corifollitropin alfa 150 μg equivalent to follitropin beta 300 IU/day for controlled ovarian hyperstimulation (COS) in older women weighing ≥50 kg undergoing IVF and/or ICSI in Vietnam?Corifollitropin alfa 150 μg was equivalent to follitropin beta 300 IU/day with respect to the number of oocytes retrieved, the ongoing, cumulative

2017 Publication 4890926 Controlled trial quality: predicted high

30. Prediction of Imminent Preeclampsia at 35-37 Weeks' Gestation. (PubMed)

Prediction of Imminent Preeclampsia at 35-37 Weeks' Gestation. In the weeks preceding the clinical onset of preeclampsia (PE) the maternal serum level of the angiogenic placental growth factor (PLGF) is decreased and that of the antiangiogenic factor soluble fms-like tyrosine kinase-1 (sFLT) is increased. Women presenting at specialist clinics with signs or symptoms of hypertensive disorders have been stratified according to concentrations of PLGF or the ratio of concentrations of sFLT and PLGF (...) to determine clinical management for the subsequent 1-4 weeks. An alternative approach for the prediction of PE is use of the competing risks model, a Bayes' theorem based method, to derive patient-specific risk for PE by various combinations of maternal characteristics and medical history with multiples of the median (MoM) values of biomarkers.To compare the performance of screening for delivery with PE at ≤2 and ≤4 weeks after assessment at 35+0 - 36+6 weeks' gestation between the use of percentile cut

2019 American Journal of Obstetrics and Gynecology

31. Prediction of small for gestational age neonates: Screening by maternal factors, fetal biometry and biomarkers at 35-37 weeks' gestation. (PubMed)

Prediction of small for gestational age neonates: Screening by maternal factors, fetal biometry and biomarkers at 35-37 weeks' gestation. Small for gestational age (SGA) neonates are at increased risk for perinatal mortality and morbidity; however, the risks can be substantially reduced if the condition is identified prenatally, because in such cases close monitoring and appropriate timing of delivery and prompt neonatal care can be undertaken. The traditional approach of identifying (...) at 36 weeks' gestation is more effective than that at 32 weeks in predicting birth of SGA neonates.To investigate the potential value of maternal characteristics and medical history, sonographically estimated fetal weight (EFW) and biomarkers of impaired placentation at 35+0- 36+6 weeks' gestation in the prediction of delivery of SGA neonates.A dataset of 19,209 singleton pregnancies undergoing screening at 35+0-36+6 weeks' gestation was divided into a training set and a validation set. The training

2019 American Journal of Obstetrics and Gynecology

32. Short-Term Outcomes of Sleeve Gastrectomy plus Jejunojejunal Bypass: a Retrospective Comparative Study with Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in Chinese Patients with BMI ≥ 35 kg/m<sup>2</sup>. (PubMed)

Short-Term Outcomes of Sleeve Gastrectomy plus Jejunojejunal Bypass: a Retrospective Comparative Study with Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in Chinese Patients with BMI ≥ 35 kg/m2. Bariatric surgery represents the most effective treatment for obesity and its related comorbidities. The present study aims to evaluate the efficacy and safety of sleeve gastrectomy plus jejunojejunal bypass (SG + JJB).This retrospective study included 244 obese patients with BMI ≥ 35 kg/m2 (...) undergoing SG + JJB (n = 83), SG (n = 82), and Roux-en-Y gastric bypass (RYGB) (n = 79). Postoperative weight loss, metabolic outcomes, nutrition status, and patients' complaints at 1-year follow-up were compared. Subgroup analyses (36 pairs of SG + JJB/SG and 37 pairs of SG + JJB/RYGB) were performed to compare weight loss and lipid profiles after matching with gender, age, and BMI.In subgroup case-matched study, SG + JJB exhibited superior weight loss effect to SG regarding total weight loss (38.8

2019 Obesity Surgery

33. Public satisfaction with GP services drops to lowest level in 35 years

Public satisfaction with GP services drops to lowest level in 35 years Public satisfaction with GP services drops to lowest level in 35 years | The King's Fund Main navigation Health and care services Leadership, systems and organisations Patients, people and society Policy, finance and performance Search term Apply Public satisfaction with GP services drops to lowest level in 35 years This content relates to the following topics: Part of Jump link block Jump to section Share this content (...) with other NHS services have not experienced such a steep decline and have tended to fluctuate year on year. And as respondents are more likely to have used GP services rather than the other services covered in the survey, this is likely to be an accurate reflection of their recent experiences. Satisfaction is usually highest among older respondents (Figure 1). For example, in 2017, satisfaction among those aged 65 or older was much higher (77 per cent) than among those aged 18 to 64 (62 per cent

2018 King's Fund blog

34. Interleukin-35 Promotes Macrophage Survival and Improves Wound Healing After Myocardial Infarction in Mice. (PubMed)

2) macrophages in infarcted hearts. IL-35 activated transcription of CX3C chemokine receptor 1(CX3CR1) and transforming growth factor beta 1 in macrophages by inducing GP130 signaling, via IL12Rβ2 and phosphorylation of STAT1 and STAT4 and subsequently promoted Ly6Clow macrophage survival and extracellular matrix deposition. Moreover, compared with control MI mice, IL-35-treated MI mice showed increased expression of α-SMA and collagen within scars, correlating with decreased left ventricular (...) Interleukin-35 Promotes Macrophage Survival and Improves Wound Healing After Myocardial Infarction in Mice. Targeting inflammation has been shown to provide clinical benefit in the field of cardiovascular diseases. Although manipulating regulatory T cell (Treg) function is an important goal of immunotherapy, the molecules that mediate their suppressive activity remain largely unknown. Interleukin 35 (IL-35), an immunosuppressive cytokine mainly produced by Tregs, is a novel member of the IL-12

2019 Circulation Research

35. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI lower than 35 kg/m<sup>2</sup> : Why caution is still needed. (PubMed)

brought by this consensus is highly relevant, the recommendation of metabolic surgery for patients with uncontrolled T2DM and a body mass index of 30 to 35 kg/m2 still lacks enough evidence. This article provides an overall view of the metabolic benefits of bariatric/metabolic surgery in patients with class 1 obesity, compares the procedure against clinical treatment, and presents our rationale for defending caution on recommending the procedure to less obese individuals.© 2019 World Obesity (...) Metabolic surgery for the treatment of type 2 diabetes in patients with BMI lower than 35 kg/m2 : Why caution is still needed. Bariatric surgery has shifted from being a risky procedure to an evidence-based one, with proven benefits on all-cause mortality, cardiovascular disease, cancer, and diabetes control. The procedure has an overall positive result on type 2 diabetes mellitus (T2DM), with a substantial number of patients achieving disease remission. This has resulted in several

2019 Obesity Reviews

36. Impact of American Academy of Pediatrics Palivizumab Guidance for Children ≥29 and &lt;35 Weeks of Gestational Age. (PubMed)

Impact of American Academy of Pediatrics Palivizumab Guidance for Children ≥29 and <35 Weeks of Gestational Age. To evaluate the impact of the American Academy of Pediatrics revised recommendations (2014) for palivizumab prophylaxis on respiratory syncytial virus (RSV) admissions and severity of illness among children ≥29 weeks and <35 weeks of gestational age.We evaluated patients hospitalized with RSV infection from October 1, 2012, through April 30, 2017. RSV hospitalizations, community (...) RSV activity, duration of hospitalization, disease severity, and mortality were reviewed. Data were compared before and after implementation of the guideline changes.A total of 91 patients were born at ≥29 weeks and <35 weeks of gestational age and hospitalized within the first year of life during the evaluation period. Gestational age, birth weight, age at diagnosis, and sex remained constant over the seasons evaluated. RSV hospitalizations and activity in the community were unchanged over 5

2019 Journal of Pediatrics

37. Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer. (PubMed)

+Foxp-3+ cells, which associated with ARG1 mRNA expression and decreased TNFA in the TU region of the lung of patients with NSCLC as compared to their CTR region. Furthermore, in the CTR region of the lung of patients with NSCLC, CD68+ macrophages were induced and correlated with IL-35+ cells. Finally, IL-35 positively correlated with TTF-1+PD-L1+ cells in the TU region of NSCLC patients.Induced IL-35+Foxp3+ cell numbers in the TU region of the lung of patients with NSCLC associated with ARG1 mRNA (...) expression and with TTF-1+PD-L1+ cells. In the tumour-free CTR area, IL-35 correlated with CD68+ macrophages. Thus inhibitors to IL-35 would probably succeed in combination with antibodies against immune checkpoints like PD-L1 and PD-1 currently used against NSCLC because they would inhibit immunosuppressive macrophages and T regulatory cells while promoting T cell-mediated anti-tumoural immune responses in the microenvironment as well as the TU region of NSCLC patients.

2019 British Journal of Cancer

38. Hemostatic characteristics of thawed, pooled cryoprecipitate stored for 35 days at refrigerated and room temperatures. (PubMed)

Hemostatic characteristics of thawed, pooled cryoprecipitate stored for 35 days at refrigerated and room temperatures. Cryoprecipitate's shelf life is limited due to concerns over decreased clotting factor activity and contamination with extended storage. Hemostatic characteristics of thawed cryoprecipitate stored up to 35 days at refrigerated and room temperatures were assessed.Pooled cryoprecipitate was thawed and aliquoted for storage at 1-6°C or 21-24°C. Samples were tested immediately (...) after thawing and at 4 h, 24 h, 72 h, and weekly for 35 days. At each time point fibrinogen, factor VIII (FVIII), and von Willebrand factor (vWF) were assessed. Thrombin generation and rotational thromboelastometry (ROTEM) were also performed. Further, packed red cells, platelet concentrates, frozen plasma, and stored cryoprecipitate were combined (1:1:1:1) to simulate massive transfusion and analyzed by ROTEM. Day 35 samples were cultured for bacterial contamination.Precipitation was observed

Full Text available with Trip Pro

2019 Transfusion

39. Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. (PubMed)

Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. To investigate the potential value of uterine artery pulsatility index (UtA-PI) and serum levels of the angiogenic placental growth factor (PlGF) and the antiangiogenic factor soluble fms-like tyrosine kinase-1 (sFlt-1) in the prediction of adverse perinatal outcome in small-for-gestational-age (SGA) and non-SGA neonates at 35-37 weeks' gestation.This was a prospective observational (...) study of 19 209 singleton pregnancies attending for a routine hospital visit at 35 + 0 to 36 + 6 weeks' gestation. This visit included recording of maternal demographic characteristics and medical history, sonographic estimation of fetal weight, color Doppler ultrasound for measurement of mean UtA-PI, and measurement of serum concentrations of PlGF and sFlt-1. Multivariable logistic regression analysis was carried out to determine which of the factors from maternal or pregnancy characteristics

2019 Ultrasound in Obstetrics and Gynecology

40. Increasing knowledge in <i>IGF1R</i> defects: lessons from 35 new patients. (PubMed)

Increasing knowledge in IGF1R defects: lessons from 35 new patients. The type 1 insulin-like growth factor receptor (IGF1R) is a keystone of fetal growth regulation by mediating the effects of IGF-I and IGF-II. Recently, a cohort of patients carrying an IGF1R defect was described, from which a clinical score was established for diagnosis. We assessed this score in a large cohort of patients with identified IGF1R defects, as no external validation was available. Furthermore, we aimed (...) to develop a functional test to allow the classification of variants of unknown significance (VUS) in vitro.DNA was tested for either deletions or single nucleotide variant (SNV) and the phosphorylation of downstream pathways studied after stimulation with IGF-I by western blot analysis of fibroblast of nine patients.We detected 21 IGF1R defects in 35 patients, including 8 deletions and 10 heterozygous, 1 homozygous and 1 compound-heterozygous SNVs. The main clinical characteristics of these patients

2019 Journal of Medical Genetics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>